Fintel reports that on July 28, 2023, TD Cowen initiated coverage of Hims & Hers Health Inc - (NYSE:HIMS) with a Outperform recommendation.
Analyst Price Forecast Suggests 53.47% Upside
As of July 6, 2023, the average one-year price target for Hims & Hers Health Inc - is 13.26. The forecasts range from a low of 10.10 to a high of $18.90. The average price target represents an increase of 53.47% from its latest reported closing price of 8.64.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Hims & Hers Health Inc - is 729MM, an increase of 18.33%. The projected annual non-GAAP EPS is -0.21.
What is the Fund Sentiment?
There are 377 funds or institutions reporting positions in Hims & Hers Health Inc -. This is an increase of 50 owner(s) or 15.29% in the last quarter. Average portfolio weight of all funds dedicated to HIMS is 0.48%, a decrease of 32.99%. Total shares owned by institutions decreased in the last three months by 7.45% to 120,960K shares. 
The put/call ratio of HIMS is 0.52, indicating a bullish outlook.
What are Other Shareholders Doing?
Institutional Venture Management XVI holds 7,709K shares representing 3.68% ownership of the company. In it's prior filing, the firm reported owning 10,209K shares, representing a decrease of 32.44%. The firm increased its portfolio allocation in HIMS by 23.46% over the last quarter.
Institutional Venture Management Xv holds 7,709K shares representing 3.68% ownership of the company. In it's prior filing, the firm reported owning 10,209K shares, representing a decrease of 32.44%. The firm increased its portfolio allocation in HIMS by 5.58% over the last quarter.
Redpoint Management holds 6,652K shares representing 3.18% ownership of the company. In it's prior filing, the firm reported owning 10,396K shares, representing a decrease of 56.28%. The firm decreased its portfolio allocation in HIMS by 24.22% over the last quarter.
NewView Capital Partners I holds 5,046K shares representing 2.41% ownership of the company. In it's prior filing, the firm reported owning 5,054K shares, representing a decrease of 0.14%. The firm increased its portfolio allocation in HIMS by 123.64% over the last quarter.
Marshall Wace, Llp holds 3,971K shares representing 1.90% ownership of the company. In it's prior filing, the firm reported owning 4,487K shares, representing a decrease of 13.00%. The firm decreased its portfolio allocation in HIMS by 14.36% over the last quarter.
Hims & Hers Health Background Information
(This description is provided by the company.)
Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide all Americans access to quality, convenient and affordable care. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California.
Additional reading:
- Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $190.8 million, up 88% year-over-year in Q1 2023 Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023 Su
- Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results Full year 2022 revenue of $526.9 million, up 94% year-over-year Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 mill
- Hims & Hers Health, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder
- Form of Change in Control and Severance Agreement.*
- List of Subsidiaries*
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
